ES2364166B1 - Huella genómica como predictor de respuesta a tratamiento. - Google Patents

Huella genómica como predictor de respuesta a tratamiento. Download PDF

Info

Publication number
ES2364166B1
ES2364166B1 ES200931311A ES200931311A ES2364166B1 ES 2364166 B1 ES2364166 B1 ES 2364166B1 ES 200931311 A ES200931311 A ES 200931311A ES 200931311 A ES200931311 A ES 200931311A ES 2364166 B1 ES2364166 B1 ES 2364166B1
Authority
ES
Spain
Prior art keywords
treatment
response
predictor
genomic
breast cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES200931311A
Other languages
English (en)
Other versions
ES2364166A1 (es
Inventor
Ramon Garcia Escudero
Jesus Maria Paramio Gonzalez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centro de Investigaciones Energeticas Medioambientales y Tecnologicas CIEMAT
Original Assignee
Centro de Investigaciones Energeticas Medioambientales y Tecnologicas CIEMAT
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro de Investigaciones Energeticas Medioambientales y Tecnologicas CIEMAT filed Critical Centro de Investigaciones Energeticas Medioambientales y Tecnologicas CIEMAT
Priority to ES200931311A priority Critical patent/ES2364166B1/es
Priority to PCT/ES2010/070874 priority patent/WO2011080373A1/es
Publication of ES2364166A1 publication Critical patent/ES2364166A1/es
Application granted granted Critical
Publication of ES2364166B1 publication Critical patent/ES2364166B1/es
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G06F19/20—
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)

Abstract

Huella genómica como predictor de respuesta a tratamiento.#La invención se relaciona con un método de predicción de la respuesta al tratamiento con un taxano más quimioterapia con un antimetabolito, un agente intercalante y un agente alquilante del ADN, en pacientes con cáncer de mama. En concreto, los autores han desarrollado un modelo mediante regresión logística en que el test genómico de 40 genes, combinado con parámetros clínicos, predice con precisión la respuesta patológica completa (RCp) al tratamiento neoadyuvante de paclitaxel más quimioterapia con fluorouracilo, adriamicina y ciclofosfamida (T/FAC) en pacientes de cáncer de mama con una expresión normal del gen HER-2. Dicho modelo tiene mejor rendimiento que las variables clínicas utilizadas rutinariamente.
ES200931311A 2009-12-31 2009-12-31 Huella genómica como predictor de respuesta a tratamiento. Expired - Fee Related ES2364166B1 (es)

Priority Applications (2)

Application Number Priority Date Filing Date Title
ES200931311A ES2364166B1 (es) 2009-12-31 2009-12-31 Huella genómica como predictor de respuesta a tratamiento.
PCT/ES2010/070874 WO2011080373A1 (es) 2009-12-31 2010-12-30 Huella genómica como predictor de respuesta a tratamiento

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200931311A ES2364166B1 (es) 2009-12-31 2009-12-31 Huella genómica como predictor de respuesta a tratamiento.

Publications (2)

Publication Number Publication Date
ES2364166A1 ES2364166A1 (es) 2011-08-26
ES2364166B1 true ES2364166B1 (es) 2012-07-10

Family

ID=44226196

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200931311A Expired - Fee Related ES2364166B1 (es) 2009-12-31 2009-12-31 Huella genómica como predictor de respuesta a tratamiento.

Country Status (2)

Country Link
ES (1) ES2364166B1 (es)
WO (1) WO2011080373A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2857191A1 (en) * 2011-11-28 2013-06-06 National Research Council Of Canada Paclitaxel response markers for cancer
WO2014080060A1 (es) * 2012-11-23 2014-05-30 Servicio Andaluz De Salud Método para predecir la respuesta al tratamiento con quimioterapia en pacientes con cáncer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2363518A1 (en) * 2000-11-21 2002-05-21 Affymetrix, Inc. Methods and computer software products for predicting nucleic acid hybridization affinity
US7526387B2 (en) * 2003-07-10 2009-04-28 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
US20060121511A1 (en) * 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
WO2008060376A2 (en) * 2006-10-04 2008-05-22 The Johns Hopkins University Algorithims for multivariant models to combine a panel of biomarkers for assessing the risk of developing ovarian cancer
EP2235211A1 (en) * 2007-12-28 2010-10-06 Ipsogen Breast cancer expresion profiling

Also Published As

Publication number Publication date
ES2364166A1 (es) 2011-08-26
WO2011080373A1 (es) 2011-07-07

Similar Documents

Publication Publication Date Title
CR9315A (es) Metodos y sistemas para el diagnostico, pronostico y seleccion del tratamiento de la leucemia
AR055594A1 (es) Prediccion de la recaida osea del cancer de mama
ES2721424T3 (es) Método de diagnóstico del cáncer de vejiga
UY31816A (es) Agente para el tratamiento y/o prevención de una enfemedad autoinmune y para la formación de células t reguladoras
ES2422739T3 (es) Composición para el diagnóstico, prevención o tratamiento de enfermedades relacionadas con células que expresan IL-8 o GRO-, que comprende MSC de UCB
WO2011095623A3 (en) miRNA IN THE DIAGNOSIS OF OVARIAN CANCER
BR112012024718A2 (pt) método para a predição da recorrência de câncer da mama sob tratamento endócrino
WO2010042831A3 (en) Diagnosis, prognosis and treatment of glioblastoma multiforme
JP2015511121A5 (es)
AR061136A1 (es) Procedimiento
ES2679373T3 (es) Nuevos ligandos de RIG-I y métodos para producirlos
AR109941A1 (es) Generación de maíz resistente al tizón de la hoja del norte
BRPI0909166A2 (pt) partícula com características topoespecíficas bipolares, e, processo de preparação das mesmas
WO2010033773A3 (en) Diagnostic, prognostic and therapeutic uses of mirs in adaptive pathways and/or disease pathways
WO2009121878A3 (en) In vitro diagnostic method for the diagnosis of somatic and ovarian cancers
CO2019003583A2 (es) Estructuras eficientes de datos para la representación de información bioinformática
WO2018125019A3 (en) Use of some mirnas for the diagnosis and treatment of diseases associated with insulin
WO2013066879A3 (en) SOLUBLE UROKINASE RECEPTOR (suPAR) IN DIABETIC KIDNEY DISEASE
ES2364166B1 (es) Huella genómica como predictor de respuesta a tratamiento.
MX2013004747A (es) Marcadores de gen de sangre periferica para el diagnostico temprano de la enfermedad de parkinson.
SG173635A1 (en) A method for the systematic evaluation of the prognostic properties of gene pairs for medical conditions, and certain gene pairs identified
SG179129A1 (en) Method for identifying whether a patient will be responder or not to immunotherapy
AR097909A1 (es) Método para determinar el pronóstico del cáncer de páncreas
ES2674053T3 (es) Diagnóstico de paraplejias espásticas hereditarias (HPS) a través de la identificación de una mutación en el gen o proteína ZFYVE26
WO2013188823A3 (en) Cancer prognostic assays

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2364166

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20120710

FD2A Announcement of lapse in spain

Effective date: 20181011